HealthTech

With RCM Staff in Short Supply, Is AI the Missing Piece?

A hefty 63% of healthcare providers are grappling with revenue cycle management ...

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint ...

Vaxcyte’s stock price {$PCVX} dropped by 50% on Monday after the company reporte...

FDA reschedules opioid-focused advisory meeting

A meeting of outside experts to discuss the FDA’s post-marketing requirements fo...

Isomorphic Labs secures $600M in funding for AI drug de...

The company will use the funds for AI research and to advance its programs in cl...

Vertex Cell Therapy Misses in the Clinic, But It Has Ot...

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell t...

Corcept shares soar after Phase 3 win in ovarian cancer

Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survi...

WELL Health to acquire control of HEALWELL AI alongside...

Vancouver-based WELL Health will assume control of HEALWELL AI upon the closing ...

WELL Health to acquire HEALWELL AI alongside Orion Heal...

Vancouver-based WELL Health will assume control of HEALWELL AI upon the closing ...

Merck’s PAH drug slashed risk of serious events in halt...

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the...

AstraZeneca’s cholesterol pill is set for Phase 3, but ...

AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believi...

Biotech markets fall as industry takes stock of Marks e...

The departure of one of the FDA’s highest-profile regulators, whose career was d...

Lilly's heart drug study shows potential for once-a-yea...

Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could b...

HIMSS and ViVE Recap – Healthcare IT Today Podcast Epis...

For the 163rd episode of the Healthcare IT Today Podcast, we are recapping the r...

LifeMine’s restructuring; Europe won’t renew authorizat...

Plus, news about ​​Opthea, Apollomics, LaunXP and AstraZeneca: LifeMine redu...

Alphabet’s Isomorphic Labs raises $600M in biotech’s la...

Google’s bet on AI in drug discovery just got a lot bigger. Isomorphic Labs ...

Inspirna, which was preparing for a Phase 3 cancer tria...

A New York City drug developer led by well-known executives and backed by some o...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.